Management of Constipation in Patients with Chronic Kidney Disease

Introduction to Constipation Management

• The American Gastroenterological Association recommends that patients with chronic kidney disease (CKD) should avoid using polyethylene glycol (PEG) without direct physician supervision due to the risk of fluid and electrolyte disturbances 1, 2
• The use of magnesium oxide is explicitly contraindicated in renal insufficiency due to the risk of hypermagnesemia, as patients with CKD cannot adequately excrete magnesium 1, 2, 3

First-Line Treatment Options

• Lactulose (15 g daily) is a safer osmotic laxative choice for patients with CKD, as it is the only osmotic agent specifically studied in special populations and does not carry renal warnings 1, 2
• Fiber supplementation (14 g/1,000 kcal intake per day) can be used for mild constipation with adequate hydration in patients with CKD 1, 2

Alternative Treatment Options

• Bisacodyl (5-10 mg daily) or senna (8.6-17.2 mg daily) can be used as stimulant laxatives for short-term or rescue use in patients with CKD, as these do not have renal contraindications 1, 2, 3
• Lubiprostone (24 μg twice daily), linaclotide (72-145 μg daily), or plecanatide (3 mg daily) are intestinal secretagogues that can be considered under specialist guidance for patients with CKD 1, 2, 3

Special Considerations

• If PEG must be used in patients with CKD, close monitoring is mandatory with regular assessment of renal function, electrolytes, and fluid status, and the lowest effective dose (17 g daily) should be used 1, 2
• Adequate but not excessive hydration should be ensured in patients with CKD using PEG, as they may have fluid restrictions 1